Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

INOpulse boosts activity levels for patients
September 2020
SHARING OPTIONS:

WARREN, N.J.—Clinical-stage biotherapeutics company Bellerophon Therapeutics Inc. reported that results in July from the first cohort of its iNO-PF Phase 2/3 study would appear in CHEST Journal. The study assessed the safety and efficacy of INOpulse inhaled nitric oxide therapy at 30 mcg/kg IBW/hr (iNO30) in patients at risk for pulmonary hypertension associated with pulmonary fibrosis. Patients received with iNO30 or placebo for eight weeks, and the patients in the iNO30 group saw clinically and statistically significant benefits in moderate to vigorous physical activity and overall activity. Activity level data were backed up by improvements in oxygen saturation and NT-proBNP, a peptide marker of right ventricular failure and disease progression. iNO30 was also found to be safe and well tolerated. Cohort 2 has also been completed, and Bellerophon is preparing to begin a pivotal Phase 3 cohort in a placebo-controlled trial of 300 patients.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.